would like to highlight MIT Holding, Inc.
). The company, through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.
In the company’s news,
MIT Holding specializes in providing value-based healthcare options anchored by a commitment to strong customer service, excellent quality of care and improved quality of life for patients. In particular, the company is a trusted provider of home-based infusion services, enabling access to an expansive medical market. According to a report by Harris Williams & Co., the United States home infusion market is currently valued at $15.9 billion and is expected to grow to $26.7 billion within the next five years. This market growth is projected to come as payers continue to recognize the significant financial benefits of performing infusion services in the home, which can provide as much as 90 percent savings over those performed in a hospital setting.
“Our in-home health recovery business, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery, is now in place,” Tommy Duncan, president of MITD, stated in a news release. “Our target audience is focused on those needing infusion for recovery.”
Currently, a large population of the potential home infusion market is being forced to visit hospitals in order to receive vital care. This is because of outdated Medicare guidelines that block payment for infusion drug patients that are treated at home. As a result, some patients are forced to endure daily hospital visits, costing the government an extra $585 million, according to the Department of Health and Human Services. However, these issues could be nearing a resolution.
In January, the Obama Administration announced plans to transition more than $100 billion in annual Medicare costs into value-based contracts designed to curb spending growth without reducing quality of care. This plan could be great news for MITD, as the company continues to realize strong market growth within the national healthcare industry. In 2014, MITD demonstrated its growth potential as it recorded an increase of more than $1.1 million in net income from operations.
As the national healthcare industry continues its shift toward value-based care, MITD is in a strong strategic position to promote sustainable growth moving forward. For prospective shareholders, the company’s proven home care services could provide a platform for favorable returns in the months to come.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.